Zentalis Pharmaceuticals Ownership | Who Owns Zentalis Pharmaceuticals?
Zentalis Pharmaceuticals Ownership Summary
Zentalis Pharmaceuticals is owned by 86.94% institutional investors, 15.61% insiders. Matrix capital management company, lp is the largest institutional shareholder, holding 19.63% of ZNTL shares. Eventide Healthcare & Life Sciences I is the top mutual fund, with 3.96% of its assets in Zentalis Pharmaceuticals shares.
ZNTL Ownership Benchmark
| Type | Name | % Inst | % Insiders | % Retail |
|---|---|---|---|---|
| Stock | Zentalis Pharmaceuticals | 86.94% | 15.61% | -2.55% |
| Sector | Healthcare Stocks | 57.39% | 9.93% | 32.68% |
| Industry | Biotech Stocks | 68.48% | 9.65% | 21.87% |
Institutional Shareholders
Top Institutional Shareholders by Total Shares
| Holder | Shares | % Holding | Value |
|---|---|---|---|
| Matrix capital management company, lp | 13.96M | 19.63% | $42.30M |
| Blackrock | 4.82M | 6.80% | $19.71M |
| Eventide asset management | 4.48M | 6.29% | $13.56M |
| Blackrock funding, inc. /de | 4.24M | 5.96% | $12.84M |
| Vanguard group | 3.27M | 4.60% | $9.91M |
| State street | 3.05M | 4.31% | $12.48M |
| Decheng capital | 2.34M | 3.29% | $7.08M |
| Morgan stanley | 1.95M | 2.75% | $7.98M |
| Opaleye management | 1.77M | 2.49% | $5.36M |
| Almitas capital | 1.63M | 2.29% | $4.93M |
Top Institutional Shareholders by % of Total Assets
| Holder | Shares | % Assets | Value |
|---|---|---|---|
| Mayo clinic | 187.14K | 25.27% | $765.41K |
| Matrix capital management company, lp | 13.96M | 1.97% | $42.30M |
| Decheng capital | 2.34M | 1.52% | $7.08M |
| Almitas capital | 1.63M | 1.08% | $4.93M |
| Opaleye management | 1.77M | 0.94% | $5.36M |
| Tybourne capital management (hk) | 961.49K | 0.73% | $2.91M |
| Bioimpact capital | 1.11M | 0.48% | $3.35M |
| 5am venture management | 490.00K | 0.35% | $1.48M |
| Eventide asset management | 4.48M | 0.25% | $13.56M |
| Anfield capital management | 129.32K | 0.14% | $391.83K |
Top Buyers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Pfizer | 953.83K | 0.11% | 953.83K |
| Morgan stanley | 1.95M | 0.00% | 913.31K |
| Acadian asset management | 1.07M | 0.01% | 804.02K |
| Opaleye management | 1.77M | 0.94% | 800.50K |
| Almitas capital | 1.63M | 1.08% | 665.97K |
Top Sellers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Fmr | 182.31K | - | -4.89M |
| Eventide asset management | 4.48M | 0.25% | -4.07M |
| Vanguard group | 3.27M | 0.00% | -1.34M |
| T. rowe price investment management | - | - | -1.33M |
| Paradigm biocapital advisors lp | - | - | -944.92K |
New Positions
| Holder | Shares | % Assets | Change | Value |
|---|---|---|---|---|
| Pfizer | 953.83K | 0.11% | 953.83K | $2.89M |
| Cubist systematic strategies | 180.22K | 0.00% | 180.22K | $546.08K |
| Bnp paribas arbitrage, snc | 176.29K | 0.00% | 176.29K | $534.16K |
| Bridgeway capital management | 175.00K | 0.01% | 175.00K | $530.25K |
| Ameriprise financial | 146.67K | 0.00% | 146.67K | $444.42K |
Sold Out
| Holder | Change |
|---|---|
| Gamma investing | -2.00 |
| Farther finance advisors | -10.00 |
| Nelson, van denburg & campbell wealth management group | -11.00 |
| Riggs asset managment | -23.00 |
| Quadrant capital group | -24.00 |
Institutional Ownership Trends
| Date | Holdings | Change % | Shares | Change % | Ownership | Change % | Increased Position | Change % | Decreased Position | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| Dec 31, 2024 | 139 | 0.72% | 61,824,330 | -12.88% | 86 | 0.87% | 85 | 19.72% | 28 | -26.32% |
| Sep 30, 2024 | 137 | -4.86% | 70,963,212 | -7.43% | 99 | 0.85% | 71 | -13.41% | 38 | -5.00% |
| Jun 30, 2024 | 144 | 2.13% | 76,655,527 | -9.95% | 108 | 0.75% | 82 | 5.13% | 40 | 11.11% |
| Mar 31, 2024 | 141 | 14.63% | 85,130,112 | 5.09% | 120 | 0.92% | 78 | 20.00% | 36 | 12.50% |
| Dec 31, 2023 | 123 | -12.14% | 81,004,402 | 1.25% | 114 | 0.89% | 65 | -2.99% | 32 | -17.95% |
Top Mutual Funds Shareholders
| Holder | Shares | % Holding | Change |
|---|---|---|---|
| Eventide Healthcare & Life Sciences I | 2.83M | 3.96% | -2.12M |
| Vanguard US Total Market Shares ETF | 1.89M | 2.64% | - |
| Eventide Gilead N | 1.64M | 2.30% | -1.94M |
| Vanguard Total Stock Mkt Idx Inv | 1.58M | 2.22% | - |
| iShares Russell 2000 ETF | 1.58M | 2.20% | -13.70K |
| Fidelity Growth Compy Commingled Pl O | 1.16M | 1.63% | - |
| PRIMECAP Odyssey Aggressive Growth | 1.13M | 1.58% | 25.10K |
| Vanguard Institutional Extnd Mkt Idx Tr | 896.55K | 1.26% | - |
| FIAM Small Cap Core CIT Cl B | 886.80K | 1.25% | 11.50K |
| Fidelity Growth Compy Commingled Pl S | 881.46K | 1.24% | -280.77K |
Recent Insider Transactions
| Date | Name | Role | Activity | Value |
|---|---|---|---|---|
| Feb 06, 2025 | Bruns Ingmar | Chief Medical Officer | Buy | $45.66K |
| Feb 03, 2025 | Vultaggio Vincent | PAO and Interim PFO | Sell | $4.48K |
| Feb 03, 2025 | Lackner Mark | Chief Scientific Officer | Sell | $24.59K |
| Feb 03, 2025 | Paul Andrea | Chief Legal Officer | Sell | $22.64K |
| Jan 31, 2025 | Skvarka Jan | - | Buy | $103.45K |
Insider Transactions Trends
| Date | Buy | Sell |
|---|---|---|
| 2025 Q1 | 3 | 4 |
| 2024 Q4 | - | 1 |
| 2024 Q2 | - | 2 |
| 2024 Q1 | - | 6 |
| 2023 Q4 | 2 | 6 |
ZNTL Ownership FAQ
Try Tickergate Pro Free
Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)
Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis
Discover trending investment themes
Find your next best investment
Research stocks using tools